NTRK2 and pulmonary arterial hypertension: In conclusion, our study showed that antagonising circ-Ntrk2 could alleviate PAH by inhibiting PASMC proliferation and reversing pulmonary vascular remodelling through the miR-296-5p/TGF-β1/p38 MAPK signal transduction axis.